Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
CJC-1295 vs IGF-1 LR3
An educational, source-based comparison of CJC-1295 and IGF-1 LR3 — how each peptide works, what it's researched for, and what to know before going deeper.
A synthetic analog of growth hormone-releasing hormone (GHRH). The non-DAC version has a short half-life that preserves pulsatile GH release, while DAC variants extend the half-life via albumin binding. Research focuses on stimulating endogenous GH and IGF-1 production via the pituitary.
- Endogenous GH pulse amplitude
- IGF-1 elevation
- Body composition in adult GH-deficient research
- Sleep architecture (slow-wave sleep)
- • GH-axis manipulation may affect glucose tolerance.
- • Banned in competitive sport (WADA).
- • Requires physician oversight in any therapeutic context.
A modified form of insulin-like growth factor-1 with an Arg3 substitution and N-terminal extension that reduces binding to IGFBPs, dramatically extending its half-life and free fraction in circulation.
- Muscle protein synthesis (preclinical)
- Tissue repair signaling
- Cell-culture growth applications
- • Hypoglycemia risk via insulin-receptor cross-activity.
- • Not FDA-approved for human therapeutic use; banned by WADA.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
Two cited studies; independent replication needed.
Early-stage research; conclusions are tentative.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| CJC-1295 | Sustained pharmacological GH activity in healthy adults via DAC technology | Journal of Clinical Endocrinology & Metabolism | 2006 | Established prolonged GH/IGF-1 elevation from single subcutaneous doses. |
| CJC-1295 | GHRH analogs and the GH-IGF-1 axis | Endocrine Reviews | 2011 | Mechanistic review of GHRH-analog pharmacology. |
| IGF-1 LR3 | Long-R3-IGF-I pharmacology and IGFBP interactions | Journal of Endocrinology | 2001 | Characterized extended half-life and bioactivity vs native IGF-1. |
Side-effect & safety grid
- GH-axis manipulation may affect glucose tolerance.
- Banned in competitive sport (WADA).
- Requires physician oversight in any therapeutic context.
- Hypoglycemia risk via insulin-receptor cross-activity.
- Not FDA-approved for human therapeutic use; banned by WADA.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
CJC-1295 vs IGF-1 LR3 — Key differences
- Class: CJC-1295 is classified as Growth Hormone Axis, while IGF-1 LR3 is Growth Factor.
- Primary research focus: CJC-1295 — endogenous gh pulse amplitude; IGF-1 LR3 — muscle protein synthesis (preclinical).
- Tag: Growth hormone vs Growth · Recovery.